Osmotica Pharmaceutical, Plc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Osmotica Pharmaceutical, Plc.
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.
October has not been kind to biotech stocks, but that hasn't stopped drug developers from launching IPOs in the US. Also, Takeda reconfigures debt ahead of Shire deal and other offerings.
The average return for the 54 drug developers that went public in the US during first three quarters of 2018 was 13.6% as of Oct. 1 versus 16.9% as of Aug. 31 for the 47 biopharma firms that launched IPOs during the first eight months of this year. September had seven new offerings after just two in August.
Public Company Edition: Eli Lilly & Co. wasted no time spinning out its animal health business Elanco, which raised $1.5bn in its public debut. Also, as the biopharma IPO tally rises, Vivo Capital launches a new public life science company fund. Meanwhile, Concordia completes its recapitalization.
- Generic Drugs
- Specialty Pharmaceuticals
- Controlled Release
- Other Names / Subsidiaries
- RevitaLid, Inc.
- Osmotica Pharmaceutical Corp
- Vertical Pharmaceuticals, Inc.
- Vertical / Trigen Holdings, LLC
- RVL Pharmaceuticals Inc.
- Lilydale Limited
- Osmotica Pharmaceuticals Limited